Click here to get full coverage on Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock - Yahoo Finance

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock  Yahoo Finance

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock - Yahoo Finance

Click here to get full coverage on Vor Biopharma slumps 26%, prices $100M equity at $10 per share - MSN

Vor Biopharma slumps 26%, prices $100M equity at $10 per share  MSN

Vor Biopharma slumps 26%, prices $100M equity at $10 per share - MSN

Click here to get full coverage on $VOR stock is down 50% today. Here's what we see in our data. - Quiver Quantitative

$VOR stock is down 50% today. Here's what we see in our data.  Quiver Quantitative

$VOR stock is down 50% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Vor Biopharma (Nasdaq: VOR) prices 10,000,000-share stock offering for $100M - Stock Titan

Vor Biopharma (Nasdaq: VOR) prices 10,000,000-share stock offering for $100M  Stock Titan

Vor Biopharma (Nasdaq: VOR) prices 10,000,000-share stock offering for $100M - Stock Titan

Click here to get full coverage on Vor Bio prices $100 million public offering of common stock - Investing.com

Vor Bio prices $100 million public offering of common stock  Investing.com

Vor Bio prices $100 million public offering of common stock - Investing.com

Click here to get full coverage on Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr - Nasdaq

Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr  Nasdaq

Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr - Nasdaq

Click here to get full coverage on Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial - Benzinga

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial  Benzinga

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial - Benzinga

Click here to get full coverage on Stil vor Talent brings 20-year celebration to Berlin’s Ritter Butzke - Electronic Groove

Stil vor Talent brings 20-year celebration to Berlin’s Ritter Butzke  Electronic Groove

Stil vor Talent brings 20-year celebration to Berlin’s Ritter Butzke - Electronic Groove

Click here to get full coverage on Investors Buy High Volume of Vor Biopharma Put Options (NASDAQ:VOR) - MarketBeat

Investors Buy High Volume of Vor Biopharma Put Options (NASDAQ:VOR)  MarketBeat

Investors Buy High Volume of Vor Biopharma Put Options (NASDAQ:VOR) - MarketBeat

Click here to get full coverage on TOURISE 2025 stellt die Initiative „Agentur-Tourismus“ vor und leistet Pionierarbeit für das Protokoll für intelligentes Reisen - The Joplin Globe

TOURISE 2025 stellt die Initiative „Agentur-Tourismus“ vor und leistet Pionierarbeit für das Protokoll für intelligentes Reisen  The Joplin Globe

TOURISE 2025 stellt die Initiative „Agentur-Tourismus“ vor und leistet Pionierarbeit für das Protokoll für intelligentes Reisen - The Joplin Globe

Click here to get full coverage on Vor Biopharma Announces $93.7 Million Public Offering - TipRanks

Vor Biopharma Announces $93.7 Million Public Offering  TipRanks

Vor Biopharma Announces $93.7 Million Public Offering - TipRanks

Click here to get full coverage on Vor Biopharma (VOR) Launches $100M Public Offering Amid Stock Dr - GuruFocus

Vor Biopharma (VOR) Launches $100M Public Offering Amid Stock Dr  GuruFocus

Vor Biopharma (VOR) Launches $100M Public Offering Amid Stock Dr - GuruFocus

Click here to get full coverage on Vor Bio launches $100M public stock offering - MSN

Vor Bio launches $100M public stock offering  MSN

Vor Bio launches $100M public stock offering - MSN

Click here to get full coverage on Vor Biopharma (Nasdaq: VOR) commences $100M stock offering; underwriters' option up to $15M - Stock Titan

Vor Biopharma (Nasdaq: VOR) commences $100M stock offering; underwriters' option up to $15M  Stock Titan

Vor Biopharma (Nasdaq: VOR) commences $100M stock offering; underwriters' option up to $15M - Stock Titan

Click here to get full coverage on Vor Biopharma stock tumbles on $100 million public offering plan - Investing.com

Vor Biopharma stock tumbles on $100 million public offering plan  Investing.com

Vor Biopharma stock tumbles on $100 million public offering plan - Investing.com

Click here to get full coverage on VOR Stock Prices at Lower End of Expected Range - GuruFocus

VOR Stock Prices at Lower End of Expected Range  GuruFocus

VOR Stock Prices at Lower End of Expected Range - GuruFocus

Click here to get full coverage on Vor Bio (NASDAQ: VOR) joins TD Cowen, Evercore chats Nov. 12 and Dec. 2; webcasts - Stock Titan

Vor Bio (NASDAQ: VOR) joins TD Cowen, Evercore chats Nov. 12 and Dec. 2; webcasts  Stock Titan

Vor Bio (NASDAQ: VOR) joins TD Cowen, Evercore chats Nov. 12 and Dec. 2; webcasts - Stock Titan

Click here to get full coverage on Vor Bio (NASDAQ: VOR) telitacicept met Phase 3 IgAN primary endpoint; China BLA filed - Stock Titan

Vor Bio (NASDAQ: VOR) telitacicept met Phase 3 IgAN primary endpoint; China BLA filed  Stock Titan

Vor Bio (NASDAQ: VOR) telitacicept met Phase 3 IgAN primary endpoint; China BLA filed - Stock Titan

Click here to get full coverage on Vor Bio (VOR) Achieves Key Milestone in Phase 3 Study for IgA Ne - GuruFocus

Vor Bio (VOR) Achieves Key Milestone in Phase 3 Study for IgA Ne  GuruFocus

Vor Bio (VOR) Achieves Key Milestone in Phase 3 Study for IgA Ne - GuruFocus

Click here to get full coverage on Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer - Yahoo Finance

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer  Yahoo Finance

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer - Yahoo Finance

Click here to get full coverage on Miniatur Wunderland Hamburg warnt vor Datendiebstahl - csoonline.com

Miniatur Wunderland Hamburg warnt vor Datendiebstahl  csoonline.com

Miniatur Wunderland Hamburg warnt vor Datendiebstahl - csoonline.com

Click here to get full coverage on Vor Bio prices public offering of 10 million shares at $10 each - MarketScreener

Vor Bio prices public offering of 10 million shares at $10 each  MarketScreener

Vor Bio prices public offering of 10 million shares at $10 each - MarketScreener

Click here to get full coverage on Vor Biopharma Inc. (VOR) Stock: Shares Surge as Company Launches $100 Million Offering - parameter.io

Vor Biopharma Inc. (VOR) Stock: Shares Surge as Company Launches $100 Million Offering  parameter.io

Vor Biopharma Inc. (VOR) Stock: Shares Surge as Company Launches $100 Million Offering - parameter.io

Click here to get full coverage on Vor Bio launches $100 million common stock offering By Investing.com - Investing.com Australia

Vor Bio launches $100 million common stock offering By Investing.com  Investing.com Australia

Vor Bio launches $100 million common stock offering By Investing.com - Investing.com Australia

Click here to get full coverage on Vor, with new CEO, changes course to target autoimmune disease - BioPharma Dive

Vor, with new CEO, changes course to target autoimmune disease  BioPharma Dive

Vor, with new CEO, changes course to target autoimmune disease - BioPharma Dive

Click here to get full coverage on Vor Biopharma stock tumbles on $100 million public offering plan By Investing.com - Investing.com South Africa

Vor Biopharma stock tumbles on $100 million public offering plan By Investing.com  Investing.com South Africa

Vor Biopharma stock tumbles on $100 million public offering plan By Investing.com - Investing.com South Africa

Click here to get full coverage on Vor Bio back from brink with autoimmune drug deal rising to $4bn - Pharmaceutical Technology

Vor Bio back from brink with autoimmune drug deal rising to $4bn  Pharmaceutical Technology

Vor Bio back from brink with autoimmune drug deal rising to $4bn - Pharmaceutical Technology

Click here to get full coverage on Vor Bio’s IgA nephropathy drug shows 55% reduction in proteinuria By Investing.com - Investing.com Nigeria

Vor Bio’s IgA nephropathy drug shows 55% reduction in proteinuria By Investing.com  Investing.com Nigeria

Vor Bio’s IgA nephropathy drug shows 55% reduction in proteinuria By Investing.com - Investing.com Nigeria

Click here to get full coverage on Vor Bio (NASDAQ: VOR) appoints Jeremy Sokolove CMO to advance BAFF/APRIL strategy - Stock Titan

Vor Bio (NASDAQ: VOR) appoints Jeremy Sokolove CMO to advance BAFF/APRIL strategy  Stock Titan

Vor Bio (NASDAQ: VOR) appoints Jeremy Sokolove CMO to advance BAFF/APRIL strategy - Stock Titan

Click here to get full coverage on We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully - Yahoo Finance

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully  Yahoo Finance

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully - Yahoo Finance

Click here to get full coverage on Chart Wise: St. Charles, Missouri, VOR Rwy 18 - FLYING Magazine

Chart Wise: St. Charles, Missouri, VOR Rwy 18  FLYING Magazine

Chart Wise: St. Charles, Missouri, VOR Rwy 18 - FLYING Magazine

Click here to get full coverage on Hoffman Reid, beneficial owner of Vor Biopharma, sells $1.13 million in VOR stock - Investing.com

Hoffman Reid, beneficial owner of Vor Biopharma, sells $1.13 million in VOR stock  Investing.com

Hoffman Reid, beneficial owner of Vor Biopharma, sells $1.13 million in VOR stock - Investing.com

Click here to get full coverage on Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions - Fierce Pharma

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions  Fierce Pharma

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions - Fierce Pharma

Click here to get full coverage on Vor Biopharma announces 1-for-20 reverse stock split effective Thursday - Investing.com

Vor Biopharma announces 1-for-20 reverse stock split effective Thursday  Investing.com

Vor Biopharma announces 1-for-20 reverse stock split effective Thursday - Investing.com

Click here to get full coverage on Vor Bio (NASDAQ: VOR) issues inducement equity to 20 new hires at $30.22 per share - Stock Titan

Vor Bio (NASDAQ: VOR) issues inducement equity to 20 new hires at $30.22 per share  Stock Titan

Vor Bio (NASDAQ: VOR) issues inducement equity to 20 new hires at $30.22 per share - Stock Titan

Click here to get full coverage on Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine - Yahoo Finance

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine  Yahoo Finance

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine - Yahoo Finance

Click here to get full coverage on Vor says drug licensed from RemeGen succeeded in Sjögren’s study - BioPharma Dive

Vor says drug licensed from RemeGen succeeded in Sjögren’s study  BioPharma Dive

Vor says drug licensed from RemeGen succeeded in Sjögren’s study - BioPharma Dive

Click here to get full coverage on Vor Bio Announces Late-Breaking Poster Presentation of - GlobeNewswire

Vor Bio Announces Late-Breaking Poster Presentation of  GlobeNewswire

Vor Bio Announces Late-Breaking Poster Presentation of - GlobeNewswire

Click here to get full coverage on Ra Capital sells Vor Biopharma (VOR) shares worth $6.2 million - Investing.com

Ra Capital sells Vor Biopharma (VOR) shares worth $6.2 million  Investing.com

Ra Capital sells Vor Biopharma (VOR) shares worth $6.2 million - Investing.com

Click here to get full coverage on New Analyst Forecast: $VOR Given $52.0 Price Target - Quiver Quantitative

New Analyst Forecast: $VOR Given $52.0 Price Target  Quiver Quantitative

New Analyst Forecast: $VOR Given $52.0 Price Target - Quiver Quantitative

Click here to get full coverage on Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise - Seeking Alpha

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise  Seeking Alpha

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise - Seeking Alpha

Click here to get full coverage on Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding - MedCity News

Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding  MedCity News

Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding - MedCity News

Click here to get full coverage on Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - Yahoo Finance

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer  Yahoo Finance

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - Yahoo Finance

Click here to get full coverage on Vor Bio appoints Jeremy Sokolove as chief medical officer - Investing.com

Vor Bio appoints Jeremy Sokolove as chief medical officer  Investing.com

Vor Bio appoints Jeremy Sokolove as chief medical officer - Investing.com

Click here to get full coverage on Vor Bio (NASDAQ: VOR) plans webcast on 48-week Phase 3 telitacicept data in Sjögren’s - Stock Titan

Vor Bio (NASDAQ: VOR) plans webcast on 48-week Phase 3 telitacicept data in Sjögren’s  Stock Titan

Vor Bio (NASDAQ: VOR) plans webcast on 48-week Phase 3 telitacicept data in Sjögren’s - Stock Titan

Click here to get full coverage on Vor Bio hires commercial chief, reuniting ex-Sarepta colleagues in freshly rebuilt C-suite - Fierce Pharma

Vor Bio hires commercial chief, reuniting ex-Sarepta colleagues in freshly rebuilt C-suite  Fierce Pharma

Vor Bio hires commercial chief, reuniting ex-Sarepta colleagues in freshly rebuilt C-suite - Fierce Pharma

Click here to get full coverage on Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer - GlobeNewswire

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer  GlobeNewswire

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer - GlobeNewswire

Click here to get full coverage on RemeGen and Vor score again with telitacicept, this time in IgA nephropathy - Fierce Pharma

RemeGen and Vor score again with telitacicept, this time in IgA nephropathy  Fierce Pharma

RemeGen and Vor score again with telitacicept, this time in IgA nephropathy - Fierce Pharma

Click here to get full coverage on Baird upgrades Vor Biopharma stock rating to Outperform on telitacicept potential - Investing.com

Baird upgrades Vor Biopharma stock rating to Outperform on telitacicept potential  Investing.com

Baird upgrades Vor Biopharma stock rating to Outperform on telitacicept potential - Investing.com

Click here to get full coverage on Vor Biopharma (VOR) Price Target Increased by 2,942.55% to 36.46 - Nasdaq

Vor Biopharma (VOR) Price Target Increased by 2,942.55% to 36.46  Nasdaq

Vor Biopharma (VOR) Price Target Increased by 2,942.55% to 36.46 - Nasdaq

Click here to get full coverage on $VOR stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$VOR stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$VOR stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - GlobeNewswire

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset  GlobeNewswire

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - GlobeNewswire

Click here to get full coverage on Vor Bio to Participate in Upcoming Investor Conferences - Yahoo Finance

Vor Bio to Participate in Upcoming Investor Conferences  Yahoo Finance

Vor Bio to Participate in Upcoming Investor Conferences - Yahoo Finance

Click here to get full coverage on Vor Biopharma's Telitacicept: A Pipeline In Itself? - RTTNews

Vor Biopharma's Telitacicept: A Pipeline In Itself?  RTTNews

Vor Biopharma's Telitacicept: A Pipeline In Itself? - RTTNews

Click here to get full coverage on Major Stock Sale Shakes Up Vor Biopharma! - TipRanks

Major Stock Sale Shakes Up Vor Biopharma!  TipRanks

Major Stock Sale Shakes Up Vor Biopharma! - TipRanks

Click here to get full coverage on Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop - Yahoo Finance

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop  Yahoo Finance

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop - Yahoo Finance

Click here to get full coverage on Major Stock Sale by Vor Biopharma Director Raises Eyebrows! - TipRanks

Major Stock Sale by Vor Biopharma Director Raises Eyebrows!  TipRanks

Major Stock Sale by Vor Biopharma Director Raises Eyebrows! - TipRanks

Click here to get full coverage on Vor Bio to wind down, halting cell therapy trials and shedding most staff - Fierce Biotech

Vor Bio to wind down, halting cell therapy trials and shedding most staff  Fierce Biotech

Vor Bio to wind down, halting cell therapy trials and shedding most staff - Fierce Biotech

Click here to get full coverage on Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio - FirstWord Pharma

Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio  FirstWord Pharma

Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio - FirstWord Pharma

Click here to get full coverage on Vor Biopharma (VOR) shares sold by RA Capital for $13.7 million - Investing.com

Vor Biopharma (VOR) shares sold by RA Capital for $13.7 million  Investing.com

Vor Biopharma (VOR) shares sold by RA Capital for $13.7 million - Investing.com

Click here to get full coverage on Stocks To Watch: Vor Biopharma Sees Relative Strength Rating Jump To 81 - Investor's Business Daily

Stocks To Watch: Vor Biopharma Sees Relative Strength Rating Jump To 81  Investor's Business Daily

Stocks To Watch: Vor Biopharma Sees Relative Strength Rating Jump To 81 - Investor's Business Daily

Click here to get full coverage on Vor Biopharma Appoints New Chief Medical Officer - TipRanks

Vor Biopharma Appoints New Chief Medical Officer  TipRanks

Vor Biopharma Appoints New Chief Medical Officer - TipRanks

Click here to get full coverage on Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel - Yahoo Finance

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel  Yahoo Finance

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel - Yahoo Finance

Click here to get full coverage on Ra capital sells Vor Biopharma (VOR) shares worth $10.3 million - Investing.com

Ra capital sells Vor Biopharma (VOR) shares worth $10.3 million  Investing.com

Ra capital sells Vor Biopharma (VOR) shares worth $10.3 million - Investing.com

Click here to get full coverage on Vor Biopharma Shares Rally After Positive Clinical Results Announced - StocksToTrade

Vor Biopharma Shares Rally After Positive Clinical Results Announced  StocksToTrade

Vor Biopharma Shares Rally After Positive Clinical Results Announced - StocksToTrade

Click here to get full coverage on Kanonenfieber Shares a New Single and a Lyric Video for "Z-Vor!" - New Album "Soldatenschicksale" Coming in 2026 - Ghost Cult Magazine

Kanonenfieber Shares a New Single and a Lyric Video for "Z-Vor!" - New Album "Soldatenschicksale" Coming in 2026  Ghost Cult Magazine

Kanonenfieber Shares a New Single and a Lyric Video for "Z-Vor!" - New Album "Soldatenschicksale" Coming in 2026 - Ghost Cult Magazine

Click here to get full coverage on Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 24,579 Shares of Stock - MarketBeat

Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 24,579 Shares of Stock  MarketBeat

VOR

Price Chart

Key Statistics

Technicals

About VOR

Latest News

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock - Yahoo Finance

Vor Biopharma slumps 26%, prices $100M equity at $10 per share - MSN

$VOR stock is down 50% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers